SCHEMBL3440871

SCHEMBL3440871

Cn1c(-c2ccco2)nc2cc(C3=NN(CCNC(=O)c4cccc(F)c4)C(=O)SC3)ccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.40
MAPT P10636 7/20 0.37
NPC1 O15118 4/20 0.37
RAB9A P51151 4/20 0.37
HPGD P15428 7/20 0.37
ALDH1A1 P00352 7/20 0.37
HSD17B10 Q99714 3/20 0.37
KDM4E B2RXH2 6/20 0.36
MEN1 O00255 6/20 0.36
KMT2A Q03164 6/20 0.36
POLB P06746 5/20 0.36
MCL1 Q07820 4/20 0.36
L3MBTL1 Q9Y468 3/20 0.36
BLM P54132 3/20 0.36
RECQL P46063 3/20 0.36
ALOX15 P16050 2/20 0.36
CASP1 P29466 1/20 0.36
CASP7 P55210 1/20 0.36
CTDSP1 Q9GZU7 1/20 0.36
NPY1R P25929 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3441014 0.92 ALDH1A1 (0.44) GAAMAPTNPC1RAB9AHPGD
SCHEMBL3441260 0.90 MEN1 (0.44) GAAMAPTNPC1RAB9AHPGD
SCHEMBL3440827 0.88 NAMPT (0.40) GAAMAPTNPC1RAB9AHPGD
SCHEMBL3440832 0.88 ALDH1A1 (0.43) GAAMAPTNPC1RAB9AHPGD
SCHEMBL3441263 0.87 RAB9A (0.41) GAAMAPTNPC1RAB9AHPGD
SCHEMBL3440836 0.86 ALDH1A1 (0.40) GAAMAPTNPC1RAB9AHPGD
SCHEMBL3440840 0.85 CCR3 (0.43) MAPTNPC1RAB9AHPGDALDH1A1
SCHEMBL3440957 0.85 RAB9A (0.39) GAAMAPTNPC1RAB9AHPGD
SCHEMBL3441017 0.85 SMN1; SMN2 (0.39) GAAMAPTNPC1RAB9AHPGD
SCHEMBL3440989 0.84 BRD4 (0.42) GAAMAPTNPC1RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232272-B2 Benzimidazoledihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 2012-07-31 US claimed
US-20100286129-A1 NOVEL BENZIMIDAZOLEDIHYDROTHIADIAZINONE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-11-11 US claimed
EP-2229385-A2 BENZIMIDAZOLEDIHYDROTHIADIAZINONE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME Merck Patent GmbH (DE) 2010-09-22 EP claimed
WO-2009062576-A2 BENZIMIDAZOLEDIHYDROTHIADIAZINONE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME MERCK PATENT GMBH (DE) 2009-05-22 WO claimed
EP-2058308-A1 Benzimidazoledihydrothiadiazinone derivatives used as fructose-1,6-biphosphatase inhibitors and pharmaceutical compositions containing same. Merck Sante (FR) 2009-05-13 EP claimed
WO-2023176784-A1 MULTILAYER STRUCTURE 三菱ケミカル株式会社 2023-09-21 WO disclosed
WO-2021256436-A1 ETHYLENE-VINYL-ALCOHOL-BASED COPOLYMER RESIN COMPOSITION, MULTILAYER STRUCTURAL BODY, AND PACKAGING BODY 三菱ケミカル株式会社 2021-12-23 WO disclosed
WO-2019163835-A1 RUBBER COMPOSITION, TIRE, CONVEYOR BELT, RUBBER CRAWLER, VIBRATION ISOLATION DEVICE, SEISMIC ISOLATION DEVICE, AND HOSE 株式会社ブリヂストン 2019-08-29 WO disclosed
WO-2019163230-A1 RUBBER COMPOSITION, TIRE, CONVEYOR BELT, RUBBER CRAWLER, VIBRATION-DAMPING DEVICE, SEISMIC ISOLATOR, AND HOSE 株式会社ブリヂストン 2019-08-29 WO disclosed
WO-2019142501-A1 RUBBER COMPOSITION, TIRE, CONVEYOR BELT, RUBBER CRAWLER, VIBRATION-DAMPING DEVICE, SEISMIC ISOLATOR, AND HOSE 株式会社ブリヂストン 2019-07-25 WO disclosed
WO-2019078083-A1 MULTI-COPOLYMER, RUBBER COMPOSITION, CROSS-LINKED RUBBER COMPOSITION, RUBBER ARTICLE, AND TIRE 株式会社ブリヂストン 2019-04-25 WO disclosed
EP-1682324-B1 METHOD AND PLANT FOR THE INTRODUCTION OF A LIQUID INTO A MOLTEN MASS UNDER PRESSURE PRYSMIAN SPA (IT) 2016-08-10 EP disclosed
US-20070248748-A1 Method and Plant for the Introduction of a Liquid Into a Molten Mass Under Pressure PRYSMIAN CAVI E SISTEMI ENERGIA S.R.L. (IT) 2007-10-25 US disclosed
EP-1682324-A1 METHOD AND PLANT FOR THE INTRODUCTION OF A LIQUID INTO A MOLTEN MASS UNDER PRESSURE Prysmian Cavi e Sistemi Energia S.r.l. (IT) 2006-07-26 EP disclosed
WO-2005042226-A1 METHOD AND PLANT FOR THE INTRODUCTION OF A LIQUID INTO A MOLTEN MASS UNDER PRESSURE PRYSMIAN CAVI E SISTEMI ENERGIA S.R.L. (IT) 2005-05-12 WO disclosed
US-20030173104-A1 Process for producing a cable, particularly for electrical power transmission or distribution, and cable produced therefrom PIRELLI CAVI E SISTEMI S.P.A. (IT) 2003-09-18 US disclosed
EP-1307890-A1 PROCESS FOR PRODUCING A CABLE, PARTICULARLY FOR ELECTRICAL POWER TRANSMISSION OR DISTRIBUTION, AND CABLE PRODUCED THEREFROM PIRELLI S.p.A. (IT) 2003-05-07 EP disclosed
WO-2002013204-A1 PROCESS FOR PRODUCING A CABLE, PARTICULARLY FOR ELECTRICAL POWER TRANSMISSION OR DISTRIBUTION, AND CABLE PRODUCED THEREFROM PIRELLI CAVI E SISTEMI S.P.A. (IT) 2002-02-14 WO disclosed
EP-1042763-A1 ELECTRICAL CABLE HAVING A SEMICONDUCTIVE WATER-BLOCKING EXPANDED LAYER PIRELLI S.p.A. (IT) 2000-10-11 EP disclosed
WO-1999033070-A1 ELECTRICAL CABLE HAVING A SEMICONDUCTIVE WATER-BLOCKING EXPANDED LAYER PIRELLI CAVI E SISTEMI S.P.A. (IT) 1999-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286129-A1 NOVEL BENZIMIDAZOLEDIHYDROTHIADIAZINONE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME FBP1, ALDOA, GCK GAA 58/4885MAPT 2599/4885NPC1 2824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.